P/E ratio for Corcept Therapeutics (CORT)

P/E ratio history for Corcept Therapeutics from 2004 to 2023

PE ratio at the end of each year

P/E ratio for similar companies or competitors

Company	P/E ratio	P/E ratio differencediff.	Country
Johnson & Johnson JNJ	10.3	-82.78%	🇺🇸 USA
Bristol-Myers Squibb BMY	14.5	-75.72%	🇺🇸 USA
Novartis NVS	26.2	-56.11%	🇨🇭 Switzerland
Eli Lilly LLY	144	140.89%	🇺🇸 USA
Pfizer PFE	14.3	-76.06%	🇺🇸 USA
Merck MRK	54.6	-8.76%	🇺🇸 USA
Esperion Therapeutics ESPR	-0.8171	-101.37%	🇺🇸 USA
MannKind Corp MNKD	-35.5	-159.36%	🇺🇸 USA
BioMarin Pharmaceutical BMRN	85.9	43.59%	🇺🇸 USA

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.